CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype

Hypertension

Volumn 64, Issue 6, 2014, Pages 1352-1361

  Abraham, Nader G ^a   Sodhi, Komal ^b   Silvis, Anne M ^b   Vanella, Luca ^c   Favero, Gaia ^d   Rezzani, Rita ^d   Lee, Craig ^e   Zeldin, Darryl C ^e   Schwartzman, Michal L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

11,12 EET; AMP activated protein kinases; aP2 protein; eNOS protein; Heme oxygenase 1; Human; Mesoderm specific transcript protein; Rat

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOCHROME P450 2J2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GLUCOSE; HEME OXYGENASE 1; INSULIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; ARACHIDONATE EPOXYGENASE; CYTOCHROME P450; DNA; FAT INTAKE;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENERGY METABOLISM; GENE TARGETING; GLUCOSE BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; VASCULAR DISEASE; WEIGHT GAIN; ANIMAL; ANIMAL FOOD; BIOSYNTHESIS; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; PHENOTYPE; PHYSIOLOGY; PLETHYSMOGRAPHY; TRANSGENIC MOUSE; VASCULAR DISEASES; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ADIPOCYTES; ADIPOSITY; ANIMAL FEED; ANIMALS; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY FATS; DISEASE MODELS, ANIMAL; DNA; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; OBESITY; PHENOTYPE; PLETHYSMOGRAPHY; VASCULAR DISEASES; VASODILATION;

EID: 84921444429     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03884     Document Type: Article

References (53)

1. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-633.
2. Brook RD, Bard RL, Rubenfre M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol. 2001;88:1264-1269.
3. Vigili De Kreutzenberg S, Kiwanuka E, Tiengo A, Avogaro A. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J. 2003;24:1210-1215.
4. Gu P, Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Rev Endocr Metab Disord. 2013;14:49-58.
5. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes. 2007;56:1517-1526.
6. Cao J, Peterson SJ, Sodhi K, Vanella L, Barbagallo I, Rodella LF, Schwartzman ML, Abraham NG, Kappas A. Heme oxygenase gene targeting to adipocytes attenuates adiposity and vascular dysfunction in mice fed a high-fat diet. Hypertension. 2012;60:467-475.
7. Sodhi K, Puri N, Inoue K, Falck JR, Schwartzman ML, Abraham NG. EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels. Prostaglandins Other Lipid Mediat. 2012;98:133-142.
8. Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced infammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005;280:4617-4626.
9. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;276:36059-36062.
10. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163-181.
11. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-infammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-1279.
12. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;433:413-420.
13. Imig JD. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin Drug Metab Toxicol. 2008;4:165-174.
14. Kim DH, Vanella L, Inoue K, Burgess A, Gotlinger K, Manthati VL, Koduru SR, Zeldin DC, Falck JR, Schwartzman ML, Abraham NG. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPAR?. Stem Cells Dev. 2010;19:1863-1873.
15. Sodhi K, Inoue K, Gotlinger KH, Canestraro M, Vanella L, Kim DH, Manthati VL, Koduru SR, Falck JR, Schwartzman ML, Abraham NG. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther. 2009;331:906-916.
16. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008;60:79-127.
17. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, Aronow WS, Ikehara S, Abraham NG. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes. 2008;57:1526-1535.
18. Vanella L, Kim DH, Sodhi K, Barbagallo I, Burgess AP, Falck JR, Schwartzman ML, Abraham NG. Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes. Prostaglandins Other Lipid Mediat. 2011;96:54-62.
19. Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, Gastaldelli A, Rezzani R, Rodella LF, Drummond G, Kusmic C, L'Abbate A, Kappas A, Abraham NG. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension. 2009;53:508-515.
20. Vanella L, Sodhi K, Kim DH, Puri N, Maheshwari M, Hinds TD, Bellner L, Goldstein D, Peterson SJ, Shapiro JI, Abraham NG. Increased hemeoxygenase 1 expression in mesenchymal stem cell-derived adipocytes decreases differentiation and lipid accumulation via upregulation of the canonical Wnt signaling cascade. Stem Cell Res Ther. 2013;4:28.
21. Kamei Y, Suganami T, Kohda T, Ishino F, Yasuda K, Miura S, Ezaki O, Ogawa Y. Peg1/Mest in obese adipose tissue is expressed from the paternal allele in an isoform-specific manner. FEBS Lett. 2007;581:91-96.
22. Takahashi M, Kamei Y, Ezaki O. Mest/Peg1 imprinted gene enlarges adipocytes and is a marker of adipocyte size. Am J Physiol Endocrinol Metab. 2005;288:E117-E124.
23. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res. 2008;49:1658-1669.
24. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L'Abbate A, Abraham NG. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res. 2009;50:1293-1304.
25. Burgess A, Li M, Vanella L, Kim DH, Rezzani R, Rodella L, Sodhi K, Canestraro M, Martasek P, Peterson SJ, Kappas A, Abraham NG. Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in both male and female obese mice. Hypertension. 2010;56:1124-1130.
26. Sacerdoti D, Bolognesi M, Di Pascoli M, Gatta A, McGiff JC, Schwartzman ML, Abraham NG. Rat mesenteric arterial dilator response to 11, 12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am J Physiol Heart Circ Physiol. 2006;291:H1999-H2002.
27. Sacerdoti D, Colombrita C, Di Pascoli M, Schwartzman ML, Bolognesi M, Falck JR, Gatta A, Abraham NG. 11, 12-epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. Prostaglandins Other Lipid Mediat. 2007;82:155-161.
28. Goodman AI, Chander PN, Rezzani R, Schwartzman ML, Regan RF, Rodella L, Turkseven S, Lianos EA, Dennery PA, Abraham NG. Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. J Am Soc Nephrol. 2006;17:1073-1081.
29. Brydun A, Watari Y, Yamamoto Y, Okuhara K, Teragawa H, Kono F, Chayama K, Oshima T, Ozono R. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res. 2007;30:341-348.
30. Deshane J, Wright M, Agarwal A. Heme oxygenase-1 expression in disease states. Acta Biochim Pol. 2005;52:273-284.
31. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005;289:F496-F503.
32. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension. 2003;42:594-599.
33. Huang H, Morisseau C, Wang J, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol. 2007;293:F342-F349.
34. Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006;290:H2187-H2195.
35. Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003;88:4130-4134.
36. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-1323.
37. Cao J, Sodhi K, Inoue K, Quilley J, Rezzani R, Rodella L, Vanella L, Germinario L, Stec DE, Abraham NG, Kappas A. Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Hum Gene Ther. 2011;22:271-282.
38. Lee CR, Imig JD, Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24:3770-3781.
39. Tabet F, Rye KA. High-density lipoproteins, infammation and oxidative stress. Clin Sci (Lond). 2009;116:87-98.
40. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358-3370.
41. Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D. Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat. 2013;107:56-63.
42. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-1663.
43. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, De Graff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, Lee CR. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular infammatory responses in mice. FASEB J. 2011;25:703-713.
44. Campbell WB. New role for epoxyeicosatrienoic acids as anti-infammatory mediators. Trends Pharmacol Sci. 2000;21:125-127.
45. Muller DN, Theuer J, Shagdarsuren E, et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol. 2004;164:521-532.
46. Burgess A, Vanella L, Bellner L, Schwartzman ML, Abraham NG. Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. Prostaglandins Other Lipid Mediat. 2012;97:1-16.
47. Chen Y, Falck JR, Manthati VL, Jat JL, Campbell WB. 20-Iodo-14, 15-epoxyeicosa-8 (Z)-enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14, 15-epoxyeicosatrienoic acid receptor. Biochemistry. 2011;50:3840-3848.
48. Issan Y, Hochhauser E, Kornowski R, Leshem-Lev D, Lev E, Sharoni R, Vanella L, Puri N, Laniado-Schwartzman M, Abraham NG, Porat E. Endothelial progenitor cell function inversely correlates with longterm glucose control in diabetic patients: association with the attenuation of the heme oxygenase-adiponectin axis. Can J Cardiol. 2012;28:728-736.
49. Xu X, Zhao CX, Wang L, Tu L, Fang X, Zheng C, Edin ML, Zeldin DC, Wang DW. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes. 2010;59:997-1005.
50. Xu X, Tu L, Feng W, Ma B, Li R, Zheng C, Li G, Wang DW. CYP2J3 gene delivery up-regulated adiponectin expression via reduced endoplasmic reticulum stress in adipocytes. Endocrinology. 2013;154:1743-1753.
51. Fedorenko A, Lishko PV, Kirichok Y. Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell. 2012;151:400-413.
52. Langin D, Larrouy D, Barbe P, Millet L, Viguerie-Bascands N, Andreelli F, Laville M, Vidal H. Uncoupling protein-2 (UCP2) and uncoupling protein-3 (UCP3) expression in adipose tissue and skeletal muscle in humans. Int J Obes Relat Metab Disord. 1999;23(suppl 6):S64-S67.
53. Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13:17-26.